RAPPORT THERAPEUTICS, INC.
Last · NasdaqGM$29.57+1.24 (+4.38%)live · yahoo · 1h ago
Market cap$1.42B48.0M sh
P/E · TTM-10.0fwd -5.8 · eps -2.96 · loss
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$23.75$52.93
Volume334.9Ksession
| Revenue | $20.0M |
|---|---|
| Operating income | $-85.0M |
| Net income | $-76.5M |
| Free cash flow | $-54.7M |
| Operating margin | -425.1% |
| Net margin | -382.4% |
| Return on equity | -18.1% |
| Period | 2026 |
Loading chart…
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.23
Est. revenue
0
Press & signals
- GlobeNewswire
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update